![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Phase 2b Study of the Interferon-Free and Ribavirin-Free Combination of Daclatasvir,
Asunaprevir, and BMS-791325 for 12 Weeks in Treatment-Naive Patients With Chronic
HCV Genotype 1 Infection
|
|
|
Reported by Jules Levin
The 64th Annual Meeting of the AASLD
Washington, DC, November 1-5, 2013
Everson GT, Sims KD, Thuluvath PJ, Lawitz E, Hassanein T, Rodriguez-Torres M, Hawkins T, Schwartz H, Rustgi V, Hinestrosa F, Levin JM, Younossi Z, Webster L, Eley T, Huang S-P, McPhee F, Grasela DM, Gardiner DF
Phase 3 Study: http://www.clinicaltrials.gov/ct2/show/NCT01973049?term=bms-791325&rank=2v
![AASLD1.gif](../images/110313/110313-9/AASLD1.gif)
![AASLD2.gif](../images/110313/110313-9/AASLD2.gif)
![AASLD3.gif](../images/110313/110313-9/AASLD3.gif)
![AASLD4.gif](../images/110313/110313-9/AASLD4.gif)
![AASLD5.gif](../images/110313/110313-9/AASLD5.gif)
![AASLD6.gif](../images/110313/110313-9/AASLD6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|